Search Articles
Reproduction permitted for personal use only. For reprints and reprint permission, contact reprints@wistechnology.com.
Exact Sciences pares its Q3 net losses
November 4, 2009
Exact Sciences, a colorectal cancer screening firm, is thriving after its move to Wisconsin, having swung from negative revenues a year ago to $1.3 million in third-quarter sales and paring its Q3 net losses by more than one-third.
The move to Wisconsin four months ago seems to agree with Exact Sciences Corp., which swung from negative revenues to positive top-line numbers during the third quarter and narrowed its Q3 net loss.
Exact Sciences said losses for the nine-month period ending Sept. 30 totaled $7.3 million, or 23 cents a share, compared with $7.6 million, or 28 cents a share for the same period last year.
President and CEO Kevin Conroy said the company is on target for getting its non-invasive, stool-based DNA screen for colorectal cancer into clinical trials. Conroy cited a deal to license Hologic's Invader molecular detection platform and integrate it into its test.
Exact Sciences pulled up stakes in Marlborough, Mass., in June after landing a $1 million loan from Wisconsin to cover the move.
The move to Wisconsin four months ago seems to agree with Exact Sciences Corp., which swung from negative revenues to positive top-line numbers during the third quarter and narrowed its Q3 net loss.
Exact Sciences said losses for the nine-month period ending Sept. 30 totaled $7.3 million, or 23 cents a share, compared with $7.6 million, or 28 cents a share for the same period last year.
President and CEO Kevin Conroy said the company is on target for getting its non-invasive, stool-based DNA screen for colorectal cancer into clinical trials. Conroy cited a deal to license Hologic's Invader molecular detection platform and integrate it into its test.
Exact Sciences pulled up stakes in Marlborough, Mass., in June after landing a $1 million loan from Wisconsin to cover the move.
Add Your Comment
Comment Policy: WTN News accepts comments that are on-topic and do not contain advertisements, profanity or personal attacks. Comments represent the views of the individuals who post them and do not necessarily represent the views of WTN Media or our partners, advertisers, or sources. Comments are moderated and not immediately posted. Your email address will not be posted.
WTN Media cannot accept liability for the content of comments posted here or verify their accuracy. If you believe this comment section is being abused, contact edit@wistechnology.com.
Advertisement
Most Popular Stories
Advertisement
Featured EventsMore…
- Apr 14 BioForward Professional Development Series - Managing Performance
- Apr 21 BioForward Professional Development Series - Project Management Essentials
- Apr 21 5th Annual Wisconsin Stem Cell Symposium -- The Road to Stem Cell Applications: Bioprocessing, Safety and Preclinical Evaluation
- Apr 22 - 23 9th Annual International Bioethics Forum - Taking the Measure of the Magic Mirror: Toward a Science of Consciousness
- Apr 22 UW-Madison IT Business Alignment Course
- May 19 - 20 Digital Healthcare Conference
- Oct 4 - 6 2010 World Stem Cell Summit
More Stories
- Twitter becoming essential tool for docs
- For Chinese people, loss of Google would mean 'nothing but darkness'
- March Madness means that half the year has passed.
- CIO drives IT business value with new perspective on processes
- Perspective matters when considering IT investment budgets
- The National Broadband Plan needs to be fixed -- already
- March Madness: IT Companies head to the big dance
- Theory meets practice in entrepreneurial bootcamp
- Core BTS will transition to new CEO based in Madison
- Measure would force White House, private sector to collaborate in cyber-crisis
WTN Media Presents
